Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceTracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche.Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.Of Cytometry, Stem Cells and Fountain of Youth.High-dimensional single-cell analysis reveals the immune signature of narcolepsy.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.Monitoring immune responses in the tumor microenvironment.Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.Analysis of Signaling Networks at the Single-Cell Level Using Mass Cytometry.Single-cell proteomics: potential implications for cancer diagnostics.Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.The helicase, DDX3X, interacts with poly(A)-binding protein 1 (PABP1) and caprin-1 at the leading edge of migrating fibroblasts and is required for efficient cell spreadingA framework for understanding and targeting residual disease in oncogene-driven solid cancers.Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.Cell Cycle Analysis by Mass Cytometry.Identification of a robust subpathway-based signature for acute myeloid leukemia prognosis using an miRNA integrated strategy.
P2860
Q26776393-12C0A65C-D695-47B6-A875-146E4E85CE9AQ27324269-E8EE1478-F78D-43C1-ABCA-00406922435BQ36266655-432C5FE0-0E49-475B-9185-8BC6CFD40AECQ36330702-C69DF74C-5D09-4FE1-B39E-F51BDF0C3678Q37415263-C58E1673-4CCE-4D23-9A2A-1F7676BF3091Q37693266-D5013B0D-3203-40C2-A8FB-3C5162A1AF41Q38376612-38C77406-3908-41C2-AF55-7BEC9D8D9083Q38380080-ECC64253-3586-4476-BDB0-1B57A2535EF9Q38666230-8C7E5577-072B-4EDF-A0FA-1947D239932DQ38668689-C5857826-5A75-46C2-AF27-931FCA13FCDAQ38741203-4D42EA50-102B-4E22-B0B7-10806B3219E1Q41190385-621C945D-766F-4E1C-A5F1-1060CCFF3DEFQ41219902-4B615236-823B-4202-A6AD-4C43B5F2BB92Q41568959-8D7B8DF6-ED5A-47FE-AFED-B5F4360B99A0Q41908997-EC4A430A-0E13-4ECF-82A1-1CCD9AC25CC1Q47414064-DB171755-AC58-4D52-88A8-AC783B602832Q47654586-BD6EEF4E-2FAF-4DF8-B011-5D45533F4F52Q52344574-58209DBD-5DB8-4BB9-95CB-B00C33848583
P2860
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@en
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@nl
type
label
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@en
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@nl
prefLabel
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@en
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@nl
P2093
P2860
P1433
P1476
Mass Cytometric Functional Pro ...... th Known Responses to Therapy.
@en
P2093
Bruno C Medeiros
Garry P Nolan
Gregory K Behbehani
Nikolay Samusik
Wendy J Fantl
Zach B Bjornson
P2860
P304
P356
10.1158/2159-8290.CD-15-0298
P577
2015-06-19T00:00:00Z